EU & EEA
For medicinal-product trials under the Clinical Trials Regulation, CTIS is the entry point for one or more EU/EEA Member States.
CTIS and EU submissions →Regulatory authority submissions
EU/EEA, UK and US applications have distinct routes, terminology and lifecycle expectations.
For medicinal-product trials under the Clinical Trials Regulation, CTIS is the entry point for one or more EU/EEA Member States.
CTIS and EU submissions →The UK has its own legislation and MHRA guidance; it is outside the CTIS route.
UK submissions →US investigational new drug programmes follow FDA requirements, with registration duties potentially applying.
US submissions →Countries, pathway, core documents, dependencies and timetable.
Inputs, versions, translations and submission-ready approvals.
Questions, decisions, amendments and agreed post-submission actions.